Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study-
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Dulaglutide (Primary) ; HM 12525A
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 20 Jul 2017 Planned End Date changed from 30 Nov 2018 to 11 Jul 2017.
- 24 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Dec 2016 Planned initiation date changed from 28 Nov 2016 to 6 Dec 2016.